Pediatric Neuroblastoma Treatment Market Report 2026

The pediatric neuroblastoma treatment market size has grown strongly in recent years. It will grow from $2.02 billion in 2025 to $2.2 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to limited access to pediatric oncology drugs, low adoption of immunotherapy, reliance on conventional chemotherapy, insufficient specialized treatment centers, fragmented clinical data on neuroblastoma.

The pediatric neuroblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing r&d in targeted therapies, increasing use of car t-cell and monoclonal antibody treatments, rising adoption of personalized medicine approaches, increasing investment in pediatric oncology infrastructure, expanding awareness programs for early detection. Major trends in the forecast period include increasing use of ai in pediatric oncology diagnostics, growing adoption of genomics-based targeted therapies, rising integration of cloud and big data for patient management, increasing use of iot-enabled monitoring in treatment protocols, rising implementation of smart manufacturing in drug production.

The increasing incidence of new pediatric neuroblastoma cases is expected to drive the growth of the pediatric neuroblastoma treatment market in the coming years. The rising prevalence of neuroblastoma is boosting demand for effective treatment options, prompting pharmaceutical companies and other stakeholders to increase investments in research and development, thereby fostering innovation across the sector. In addition, the introduction of advanced diagnostic technologies and screening methods has enabled earlier detection of neuroblastoma, supporting timely intervention and improved clinical outcomes. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization representing oncology professionals and physicians, neuroblastoma affects around 700 to 800 children annually in the United States. The disease accounts for about 6% of all childhood cancers in the country and impacts nearly 90% of children under the age of five. Consequently, the growing number of new pediatric neuroblastoma cases is contributing to the expansion of the pediatric neuroblastoma treatment market.

Leading companies operating in the pediatric neuroblastoma treatment market are focusing on the development of advanced technologies, such as antibody-based approaches, to improve targeted therapy effectiveness and enhance patient outcomes. Antibody technologies include a range of techniques and tools used for the development, production, and application of antibodies in diagnostics, therapeutics, and research. For example, in August 2023, Renaissance Pharma Ltd, a UK-based clinical-stage biopharmaceutical company, introduced Hu14.18K322A. This therapy targets GD2, a disialoganglioside expressed on the surface of neuroblastoma cells. By binding to GD2, Hu14.18K322A engages immune effector cells to attack and destroy tumor cells, which may lead to improved outcomes for patients with high-risk neuroblastoma.

In September 2025, Serb Pharmaceuticals, a US-based biopharmaceutical company specializing in rare and oncology diseases, acquired Y-mAbs Therapeutics, Inc. for an undisclosed sum. Through this acquisition, Serb seeks to strengthen its pediatric oncology portfolio, obtain access to Y-mAbs’ advanced neuroblastoma treatment, and accelerate the commercial expansion of DANYELZA for high-risk pediatric neuroblastoma. Y-mAbs Therapeutics is a US-based biopharmaceutical company focused on antibody-based cancer treatments, including its flagship anti-GD2 monoclonal antibody DANYELZA, developed for relapsed or refractory high-risk pediatric neuroblastoma.

Major companies operating in the pediatric neuroblastoma treatment market are United Therapeutics Corporation, APEIRON Biologics AG, Cell Ectar Biosciences Inc., Pfizer Inc., MacroGenics Inc., Bayer AG, Provectus Biopharmaceuticals Inc., Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Clarity Pharmaceuticals, CureSearch for Children's Cancer, Novartis AG, Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Eisai Co. Ltd.

North America was the largest region in the pediatric neuroblastoma treatment market in 2025. The regions covered in the pediatric neuroblastoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric neuroblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the pediatric neuroblastoma treatment market by increasing the cost of imported chemotherapy drugs, monoclonal antibodies, and CAR T-cell therapy equipment, impacting hospitals and specialty clinics in regions like North America and Europe. While tariffs have temporarily slowed the adoption of advanced therapies, they have also encouraged domestic production, innovation in cost-effective treatment solutions, and optimization of supply chains for critical oncology drugs.

The pediatric neuroblastoma treatment market research report is one of a series of new reports that provides pediatric neuroblastoma treatment market statistics, including pediatric neuroblastoma treatment industry global market size, regional shares, competitors with a pediatric neuroblastoma treatment market share, detailed pediatric neuroblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric neuroblastoma treatment industry. This pediatric neuroblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric neuroblastoma treatment refers to the medical management of neuroblastoma, a cancer affecting the nervous system that primarily occurs in children. Treatment typically involves a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies based on disease stage and risk classification.

The main treatment approaches for pediatric neuroblastoma include immunotherapy, chemotherapy, radiation therapy, and other therapeutic options. Immunotherapy utilizes the immune system to combat cancer cells and is applied across low-risk, intermediate-risk, and high-risk patient groups, with treatment delivered through hospitals, specialty clinics, and other healthcare settings.

The pediatric neuroblastoma treatment market consists of revenues earned by entities by providing pediatric neuroblastoma treatment services such as stem cell therapy, supportive care and blood transfusions. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric neuroblastoma treatment market also includes sales of pain management medications, chemotherapy drugs and immunotherapy agents which are used in providing pediatric neuroblastoma treatment services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.